UBS has initiated coverage of CoreWeave with a Buy rating and a price target of $120, indicating a potential upside of approximately 40%. KeyBanc has also initiated Guardian Pharmacy Services as overweight, citing its strong position in the long-term care pharmacy market.
Wolfe has reiterated Amazon as outperform, raising its price target to $320 due to better-than-expected AWS revenue and operating income estimates. BMO initiated HCA Healthcare as outperform, emphasizing its resilience amid challenging market conditions. Morgan Stanley maintains an overweight rating on SpaceX, noting limited immediate threat to major wireless companies.
Wells Fargo initiated Beta Bionics as overweight, projecting a 38% revenue CAGR through 2030. Oppenheimer initiated Teva Pharmaceuticals as outperform, forecasting growth potential. Bernstein initiated coverage on Amphenol and TE Connectivity as outperform, highlighting their upside in the interconnect space.
Rosenblatt reiterated Palantir as buy, pointing to its FAA partnership as a significant opportunity. UBS also initiated several bitcoin miners, including Core Scientific and Hut 8, with Buy ratings, anticipating growth driven by AI adoption. Seaport initiated Marvell as buy, citing its growth prospects in AI. Stifel upgraded Microsoft to buy, noting strong Azure performance.
Citi raised its price target on Micron ahead of earnings, while Bank of America reiterated Apple as buy, observing stable iPhone lead times. JPMorgan upgraded BP and Graphic Packaging to overweight, citing favorable macro conditions and attractive valuations. Citi initiated Madrigal Pharmaceuticals and Maze Therapeutics as buy, highlighting their potential.
Needham initiated Belden as buy, recognizing its benefits from reshoring. Oppenheimer initiated The Toro Company as outperform, suggesting compelling investment opportunities